Musashi 2 Mouse anti-Human, Mouse, Clone: C1, eBioscience™

Mouse Monoclonal Antibody

Overview
Brand: Affymetrix eBioscience

Manufacturer Part Number: 14-9677-80

25UG Anti-Human/Mouse Musashi-2 Purified

Code: NEW

Additional Details:
Additional Details: Weight: 0.09500kg



Disclaimers: For Research Use Only.

Product Code. 15527606

Quantity Price
1 £ 92.2 / 25µg
Estimated Shipment date
from Supplier 09-12-2016
Add to basket


Description and Specification

Specification

Antigen Musashi 2
Applications Immunocytochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Microscopy
Applications Western Blotting
Clone C1
Concentration 0.5mg/mL
Conjugate Unlabeled
Format Purified
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Host Species Mouse
Isotype IgG3
Quantity 25μg
Regulatory Status RUO
Species Reactivity Human, Mouse
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal

The monoclonal antibody C1 recognizes human and mouse Musashi-2 (Msi2), a highly conserved RNA-binding protein. Musashi-2 contains two RNA-recognition domains and is expressed as one of two isoforms of 36 and 37kDa. Musashi 2 with its family member Musashi-1, are expressed at high levels in stem and tumor cells. During neural development, Musashi-2 is expressed in progenitor cells in the ventricular and subventricular zones, while postnatally, Musashi-2 expression is limited to multiple subsets of neurons and astrocytes in addition to adult stem cell populations. Functionally, Musashi-2 associates with Sox2 and is required for self-renewal of embryonic stem cells. Much like its role in maintaining stemness in neural progenitors, Musashi-2 is expressed in hematopoetic stem cells and plays a similar role in maintaining self-renewal. Musashi-2 has been found to be overexpressed in human myeloid leukemia and the levels of expression correlate with decreased survival. Musashi-2 may serve as a prognostic marker for acute myeloid leukemia (AML).